



New and Imminent Therapies for AD: Impact on the ADRD Research Landscape

Suzanne Craft, PhD Director Wake Forest University School of Medicine ADRC





Wake Forest University School of Medicine

Disclosures

- S.C. is a Scientific Advisory Board member for T3D Therapeutics
- Content will include reference to commercial products; however, generic and alternative products will be discussed whenever possible
- Investigational products and their ongoing trials will be discussed



The framework:

- Two new therapies for AD were FDA-approved in the past year
- Results of Clarity AD trial promising, though many questions remain
 - Diversity
 - Responder characteristics
 - Safety
 - Cost and access



Lecanemab in Early Alzheimer's Disease


C.H. van Dyck, C.J. Swanson, P. Aisen, R.J. Bateman, C. Chen, M. Gee, M. Kanekiyo, D. Li, L. Reyderman, S. Cohen, L. Froelich, S. Katayama, M. Sabbagh, B. Vellas, D. Watson, S. Dhadda, M. Irizarry, L.D. Kramer, and T. Iwatsubo


 Today's panel will not focus on strengths or limitations of newly approved treatments, but implications for current and future AD research





Wave theory of scientific progress


- Advent of initial disease-modifying therapies often precedes proliferation of new treatments
- Example: Cancer














Will AD therapeutics mirror this pattern?

Publications related to AD therapeutics since 1965

PER 100,000 PUBMED CITATIONS




MADE WITH GITHUB.IO/PUBMED-BY-YEAR




Will AD therapeutics mirror this pattern?

31 agents currently in Phase 3 trials



PER 100,000 PUBMED CITATIONS



Cummings et al., TRCI, 2022




Will AD therapeutics mirror this pattern?

152 NIH-funded non-pharmacologic trials in progress



PER 100,000 PUBMED CITATIONS





Charge for the Panel

- Discuss the anticipated impact of impending disease modifying treatments for AD on ongoing trials and observational studies
- Describe strategies planned to address impact
- Discuss issues to be considered for planning future studies
- Provide innovative ideas for a positive path forward during this time of opportunity



Our Panel



Reisa Sperling, MD



Walter 'Bud' Kukull, PhD



Liana Apostolova, MD, MSc, FAAN

Ron Petersen, MD, PhD





Randall Bateman, MD